A Study of AK129 in Patients With Advanced Malignant Tumors

StatusCompleted
PhasePhase 1
SponsorAkeso
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 6 more changesShow less
    • Final enrollment: 57 participants (planned 182)
    • Primary completion date changed from estimate of Feb 2026 to Jun 9, 2026
    • Start date: Mar 2, 2023 to Mar 3, 2023
    • Eligibility criteria expanded, about 28 words
    • Secondary endpoints: details revised at 1 of 14 entries
    • Site details revised
  2. Primary completion date: Feb 2025 to Feb 2026
    • Study completion date: Feb 2025 to Jun 2026
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 15, 2023 to Mar 2, 2023
    • Site details revised
    v3
  4. Start date: Jan 15, 2023 to Feb 15, 2023
    • Enrollment target: 181 to 182
    • Eligibility criteria expanded, about 36 words
    • Secondary endpoints: 15 to 14
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Akeso
97 trials monitored
See 1 trial at risk
A Phase Ia/Ib, open label, dose escalation and dose extension trial of Anti-PD-1 and LAG-3 bispecific antibody, AK129, to evaluate the safety, tolerability and antitumor efficacy in patients with advanced malignant tumors
Trial Details
NCT Number NCT05645276
Lead Sponsor Akeso
Conditions
(from sponsor)		 Advanced Malignant Tumors(Stage IA-IB)
Enrollment 57 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov